Bersanlimab

DB17377InvestigationalProtein Based Therapies

Bersanlimab is an investigational monoclonal antibody directed against intercellular adhesion molecule 1 (ICAM-1).

Mechanism
Curator reviewed
Also known as
Anti-icam-1 monoclonal antibody bi-505 · Immunoglobulin g1-lambda, anti-(homo sapiens icam1(intercellular adhesion molecule 1, icam-1, cd54)), human monoclonal antibody · Immunoglobulin g1, anti-(human intercellular adhesion molecule icam-1) (human monoclonal bi-505 .gamma.1-chain), disulfide with monoclonal bi-505 light-chain, dimer
Code names
BI-505

Resolves to

Compound
UNIIMP3N1L4OR6CAS1987854-08-9
Targets
P05362ICAM1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Bersanlimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In